|13.90||+0.3400||+2.51%||Vol 333.68K||1Y Perf 24.46%|
|Jul 7th, 2020 11:45 DELAYED|
|- -%||- -%|
|Target Price||28.50||Analyst Rating||Strong Buy 1.17|
|Potential %||104.89||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||100/100/100||Value Ranking||— -|
|Insiders Value % 3/6/12 mo.||100/100/100||Growth Ranking||— -|
|Insiders Shares Cnt. % 3/6/12 mo.||100/100/100||Income Ranking||— -|
|Market Cap||673.73M||Earnings Rating||Strong Buy|
|Price Range Ratio 52W %||66.62||Earnings Date||4th Aug 2020|
Today's Price Range
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||4th Aug 2020|
|Estimated EPS Next Report||-0.27|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||997.67K|
|Avg. Monthly Volume||1.85M|
|Avg. Quarterly Volume||971.87K|
Provention Bio Inc. (NASDAQ: PRVB) stock closed at 13.56 per share at the end of the most recent trading day (a -5.11% change compared to the prior day closing price) with a volume of 1.35M shares and market capitalization of 673.73M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 13 people. Provention Bio Inc. CEO is Ashleigh Palmer.
The one-year performance of Provention Bio Inc. stock is 24.46%, while year-to-date (YTD) performance is -8.99%. PRVB stock has a five-year performance of %. Its 52-week range is between 4.72 and 18.5, which gives PRVB stock a 52-week price range ratio of 66.62%
Provention Bio Inc. currently has a PE ratio of -, a price-to-book (PB) ratio of 11.25, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -69.06%, a ROC of -76.54% and a ROE of -74.74%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Provention Bio Inc., there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.27 for the next earnings report. Provention Bio Inc.’s next earnings report date is 04th Aug 2020.
The consensus rating of Wall Street analysts for Provention Bio Inc. is Strong Buy (1.17), with a target price of $28.5, which is +104.89% compared to the current price. The earnings rating for Provention Bio Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Provention Bio Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Provention Bio Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 15.09, ATR14 : 1.28, CCI20 : -68.89, Chaikin Money Flow : -0.09, MACD : 0.14, Money Flow Index : 38.61, ROC : -15.04, RSI : 45.28, STOCH (14,3) : 7.34, STOCH RSI : 0.00, UO : 37.04, Williams %R : -92.67), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Provention Bio Inc. in the last 12-months were: Anthony Digiandomenico (Buy at a value of $379 950), Ashleigh Palmer (Buy at a value of $145 764), Eleanor L. Ramos (Buy at a value of $28 680), Francisco Leon (Buy at a value of $147 749), Jason Hoitt (Buy at a value of $24 435), Jeffrey Bluestone (Option Excercise at a value of $76 101)
Copyright (c) 2020. All rights reserved. Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.com, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.